FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008843259> ?p ?o ?g. }

• W3008843259 endingPage "2892" @default.
• W3008843259 startingPage "2881" @default.
• W3008843259 abstract "Abstract Objective PsA patients who achieved sustained minimal disease activity (sMDA) had less subclinical atherosclerosis progression. The vascular effects of achieving other potential treatment targets, including the PsA Disease Activity Score (PASDAS) and the Disease Activity in PsA (DAPSA) score, remained uncertain. This study aimed to compare the vascular effects of achieving different treatment targets in PsA patients. Method This is a post hoc analysis of a 2 year treat-to-target study aimed at MDA. A total of 101 consecutive PsA patients without overt cardiovascular disease were recruited. High-resolution carotid ultrasound and arterial stiffness markers were assessed annually. Low disease activity (LDA) was defined as MDA, DAPSA ≤14 or PASDAS ≤3.2. Sustained disease control was defined as achieving these targets at each visit from month 12 until month 24. Results Ninety patients [52 male (57.8%), age 50 years (s.d. 11)] who completed 24 months of follow-up were included in this analysis. A total of 44%, 48% and 45% of patients achieved sustained DAPSA LDA (sDAPDA-LDA), sustained PASDAS LDA (sPASDAS-LDA) and sMDA, respectively. Patients who achieved sMDA had significantly less progression of carotid intima-media thickness than those who did not (P = 0.031). Using multivariate analysis, achieving sMDA and sPASDAS-LDA had a protective effect on plaque progression, less increase in total plaque area, reduced mean intima-media thickness and reduced augmentation index after adjusting for covariates. In contrast, no significant differences in the progression of vascular parameters were demonstrated between patients who did or did not achieve sDAPSA-LDA. Conclusion Achieving sMDA/sDASPAS-LDA, but not sDAPSA-LDA, was associated with a protective effect in subclinical atherosclerosis and arterial stiffness progression. A multidimensional domain of disease control might be better in minimizing cardiovascular risk in PsA." @default.
• W3008843259 created "2020-03-06" @default.
• W3008843259 creator A5001005560 @default.
• W3008843259 creator A5002146323 @default.
• W3008843259 creator A5006627645 @default.
• W3008843259 creator A5015951644 @default.
• W3008843259 creator A5019007376 @default.
• W3008843259 creator A5032650852 @default.
• W3008843259 creator A5037376812 @default.
• W3008843259 creator A5039003094 @default.
• W3008843259 creator A5039547212 @default.
• W3008843259 creator A5041570474 @default.
• W3008843259 creator A5061964943 @default.
• W3008843259 creator A5063429550 @default.
• W3008843259 creator A5069810420 @default.
• W3008843259 creator A5083623343 @default.
• W3008843259 creator A5083802469 @default.
• W3008843259 date "2020-02-22" @default.
• W3008843259 modified "2023-09-26" @default.
• W3008843259 title "Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis—which target should we choose?" @default.
• W3008843259 cites W1967769016 @default.
• W3008843259 cites W1984438829 @default.
• W3008843259 cites W1996229698 @default.
• W3008843259 cites W2008311984 @default.
• W3008843259 cites W2014286422 @default.
• W3008843259 cites W2039945245 @default.
• W3008843259 cites W2040739084 @default.
• W3008843259 cites W2045284061 @default.
• W3008843259 cites W2056516039 @default.
• W3008843259 cites W2068214501 @default.
• W3008843259 cites W2069488421 @default.
• W3008843259 cites W2096606701 @default.
• W3008843259 cites W2099148197 @default.
• W3008843259 cites W2104159475 @default.
• W3008843259 cites W2106257610 @default.
• W3008843259 cites W2113717019 @default.
• W3008843259 cites W2128325185 @default.
• W3008843259 cites W2133701923 @default.
• W3008843259 cites W2141321661 @default.
• W3008843259 cites W2154464235 @default.
• W3008843259 cites W2162452434 @default.
• W3008843259 cites W2169773326 @default.
• W3008843259 cites W2173403513 @default.
• W3008843259 cites W2203272329 @default.
• W3008843259 cites W2258730682 @default.
• W3008843259 cites W2411832958 @default.
• W3008843259 cites W2426579086 @default.
• W3008843259 cites W2569653437 @default.
• W3008843259 cites W2590926956 @default.
• W3008843259 cites W2621044977 @default.
• W3008843259 cites W2765277061 @default.
• W3008843259 cites W2766700953 @default.
• W3008843259 cites W2769953079 @default.
• W3008843259 cites W2886277391 @default.
• W3008843259 cites W2888516875 @default.
• W3008843259 cites W2889927551 @default.
• W3008843259 cites W2896405515 @default.
• W3008843259 cites W2899301382 @default.
• W3008843259 cites W2948495609 @default.
• W3008843259 doi "https://doi.org/10.1093/rheumatology/keaa025" @default.
• W3008843259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32087023" @default.
• W3008843259 hasPublicationYear "2020" @default.
• W3008843259 type Work @default.
• W3008843259 sameAs 3008843259 @default.
• W3008843259 citedByCount "5" @default.
• W3008843259 countsByYear W30088432592021 @default.
• W3008843259 countsByYear W30088432592022 @default.
• W3008843259 crossrefType "journal-article" @default.
• W3008843259 hasAuthorship W3008843259A5001005560 @default.
• W3008843259 hasAuthorship W3008843259A5002146323 @default.
• W3008843259 hasAuthorship W3008843259A5006627645 @default.
• W3008843259 hasAuthorship W3008843259A5015951644 @default.
• W3008843259 hasAuthorship W3008843259A5019007376 @default.
• W3008843259 hasAuthorship W3008843259A5032650852 @default.
• W3008843259 hasAuthorship W3008843259A5037376812 @default.
• W3008843259 hasAuthorship W3008843259A5039003094 @default.
• W3008843259 hasAuthorship W3008843259A5039547212 @default.
• W3008843259 hasAuthorship W3008843259A5041570474 @default.
• W3008843259 hasAuthorship W3008843259A5061964943 @default.
• W3008843259 hasAuthorship W3008843259A5063429550 @default.
• W3008843259 hasAuthorship W3008843259A5069810420 @default.
• W3008843259 hasAuthorship W3008843259A5083623343 @default.
• W3008843259 hasAuthorship W3008843259A5083802469 @default.
• W3008843259 hasConcept C113280763 @default.
• W3008843259 hasConcept C126322002 @default.
• W3008843259 hasConcept C141071460 @default.
• W3008843259 hasConcept C164705383 @default.
• W3008843259 hasConcept C2775850156 @default.
• W3008843259 hasConcept C2776260265 @default.
• W3008843259 hasConcept C2779134260 @default.
• W3008843259 hasConcept C67761136 @default.
• W3008843259 hasConcept C71924100 @default.
• W3008843259 hasConcept C84393581 @default.
• W3008843259 hasConcept C90924648 @default.
• W3008843259 hasConceptScore W3008843259C113280763 @default.
• W3008843259 hasConceptScore W3008843259C126322002 @default.
• W3008843259 hasConceptScore W3008843259C141071460 @default.
• W3008843259 hasConceptScore W3008843259C164705383 @default.

• next